News Extra [these Stories Appear Only On The Web]

Combination therapy reduces symptoms and joint erosion in rheumatoid arthritis

BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7439.544-c (Published 04 March 2004) Cite this as: BMJ 2004;328:544
  1. Susan Mayor
  1. London

    The combination of etanercept (a drug that blocks tumour necrosis factor) and methotrexate achieves significantly greater reduction in symptoms and joint erosion than either drug used alone, a trial published in the Lancet last week has found.

    The study randomised 686 participants with active, adult onset, rheumatoid arthritis to etanercept (25 mg subcutaneously twice a week) or oral methotrexate (up to 20 mg every week), or a combination of both drugs.

    The mean age of the participants was about 53 years, with mean disease duration of 6.3 to 6.8 years (range 6 months to 20 years). All participants …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe